Goldman Sachs Group, Inc. (The) lowered shares of Quest Diagnostics Incorporated (NYSE:DGX) from a conviction-buy rating to a buy rating in a report released on Tuesday morning. They currently have $113.00 target price on the medical research company’s stock, down from their previous target price of $121.00.

DGX has been the subject of several other research reports. ValuEngine raised shares of Quest Diagnostics from a hold rating to a buy rating in a research report on Friday, September 1st. Zacks Investment Research downgraded shares of Quest Diagnostics from a buy rating to a hold rating in a research report on Thursday, August 3rd. BidaskClub downgraded shares of Quest Diagnostics from a buy rating to a hold rating in a research report on Monday, July 24th. Credit Suisse Group reaffirmed a neutral rating and set a $110.00 price objective (up previously from $83.00) on shares of Quest Diagnostics in a research report on Thursday, July 13th. They noted that the move was a valuation call. Finally, Raymond James Financial, Inc. reaffirmed a market perform rating on shares of Quest Diagnostics in a research report on Monday, September 25th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $110.41.

Shares of Quest Diagnostics (NYSE DGX) traded up 0.53% on Tuesday, reaching $91.34. 187,475 shares of the company were exchanged. The company has a market cap of $12.46 billion, a price-to-earnings ratio of 18.42 and a beta of 0.65. The company’s 50-day moving average price is $101.50 and its 200 day moving average price is $104.98. Quest Diagnostics has a 12 month low of $79.12 and a 12 month high of $112.96.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $1.55 EPS for the quarter, topping the consensus estimate of $1.42 by $0.13. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. Quest Diagnostics had a net margin of 9.28% and a return on equity of 15.66%. The company’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.34 EPS. On average, equities research analysts expect that Quest Diagnostics will post $5.66 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Quest Diagnostics Incorporated (DGX) Downgraded to Buy at Goldman Sachs Group, Inc. (The)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/10/11/quest-diagnostics-incorporated-dgx-downgraded-to-buy-at-goldman-sachs-group-inc-the.html.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 18th. Investors of record on Tuesday, October 3rd will be given a $0.45 dividend. This represents a $1.80 annualized dividend and a yield of 1.98%. The ex-dividend date is Monday, October 2nd. Quest Diagnostics’s payout ratio is currently 36.29%.

In other Quest Diagnostics news, Chairman Stephen H. Rusckowski sold 2,525 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $108.03, for a total transaction of $272,775.75. Following the transaction, the chairman now directly owns 168,413 shares in the company, valued at approximately $18,193,656.39. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey M. Leiden sold 1,304 shares of the firm’s stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $108.73, for a total value of $141,783.92. Following the transaction, the director now owns 6,296 shares in the company, valued at $684,564.08. The disclosure for this sale can be found here. In the last three months, insiders sold 161,996 shares of company stock valued at $17,517,207. 1.75% of the stock is currently owned by insiders.

Large investors have recently modified their holdings of the business. WFG Advisors LP lifted its stake in Quest Diagnostics by 45.3% during the 2nd quarter. WFG Advisors LP now owns 966 shares of the medical research company’s stock valued at $107,000 after acquiring an additional 301 shares in the last quarter. Sun Life Financial INC lifted its stake in Quest Diagnostics by 14,142.9% during the 2nd quarter. Sun Life Financial INC now owns 997 shares of the medical research company’s stock valued at $111,000 after acquiring an additional 990 shares in the last quarter. Parallel Advisors LLC lifted its stake in Quest Diagnostics by 16.1% during the 1st quarter. Parallel Advisors LLC now owns 1,279 shares of the medical research company’s stock valued at $137,000 after acquiring an additional 177 shares in the last quarter. Acrospire Investment Management LLC lifted its stake in Quest Diagnostics by 300.0% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,600 shares of the medical research company’s stock valued at $178,000 after acquiring an additional 1,200 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in Quest Diagnostics during the 2nd quarter valued at $180,000. Institutional investors and hedge funds own 87.10% of the company’s stock.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Stock Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related stocks with our FREE daily email newsletter.